Tag Archives: NASDAQ

Now You Can Buy Weed Stocks on the U.S. Stock Exchange

Now You Can Buy Weed Stocks on the U.S. Stock Exchange

Now You Can Buy Weed Stocks on the U.S. Stock Exchange

For those hoping to get in on the cannabis stock game, a Canadian company has gotten approval to start trading on the NASDAQ. It’s the U.S. Stock Exchange’s first listed marijuana company, according to VICE.

GrowPros

Neptune and Tetra Bio-Pharma Enter Co-Development Agreement for Purified Cannabinoid Oil-Based Products targeting Pain and Inflammation

LAVAL, Quebec, Feb. 12, 2018 /Weed Wire/ – Tetra Bio-Pharma Inc. (“Tetra”) (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ( “Neptune”) (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets.

Merry Munchie Meal

Jack in the Box Partners with Merry Jane to Launch Merry Much Meal

SAN DIEGO, Calif., Dec. 22, 2017 /Weed Wire/ —Today, California-based fast food restaurant, Jack in the Box®, announces its partnership with the leading cannabis media and lifestyle platform, MERRY JANE®. Together, the brands will launch the limited-time offer MERRY Munchie Meal TM in select Long Beach, California locations

Marijuana Index Gains Continue As Pot Stocks Anticipate Prohibition Repeal

Marijuana Index Gains Continue As Pot Stocks Anticipate Prohibition Repeal

It was another big day of gains on Tuesday for the North American Marijuana Index, even as some investors anxiously wait for the Fed to announce an interest rate hike in the next 24 hours.

Merger Intends to Make High Times Publicly Traded Company

High Hopes: Merger Intends to Make High Times Publicly Traded Company

On July 27, 2017, Hightimes Holding Corp., the company behind High Times magazine, announced a merger agreement with Origo Acquisition Corporation (NASDAQ:OACQ), a special purpose acquisition company, as a means of making High Times a publicly traded company.

Hightimes Holding Corp. Seeks Public Listing Through Business Combination with Origo Acquisition Corporation

LOS ANGELES and NEW YORK, July 27, 2017 /Weed Wire/ – Hightimes Holding Corp. (“High Times”), publisher of HIGH TIMES® magazine and a leading voice of the cannabis community since 1974, and Origo Acquisition Corporation (NASDAQ: OACQ) (“Origo”), a special purpose acquisition company, announced that they have entered into a definitive merger agreement. Upon closing of the transaction, High Times will be a publicly traded company.

GWPH Phase 3 Results

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology

LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome

LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.

https://marijuanaindex.com/stock-quotes/north-american-marijuana-index/

A Survey Of The North American Marijuana Index – Part One

In this survey we will be reviewing the stocks that make up the North American Marijuana Index. In Part 1, we’ll look at Canopy Growth Corp. (OTCPK:TWMJF), GW pharmaceuticals (NASDAQ:GWPH), Axim Biotechnologies Inc. (OTCQB:AXIM), and United Cannabis Corp. (OTCQB:CNAB).

Zynerba

Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis

DEVON, Penn., March 13, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures.

Mentor Capital

Mentor Capital Acquires $1.0 Million of GW Pharmaceuticals, Plc

SAN DIEGO, Calif., March 3, 2017/Weed Wire/ — Mentor Capital, Inc. (OTCQB: MNTR) announced it has taken a $1.0 million position in the stock of GW Pharmaceuticals, Plc (NASDAQ: GWPH), a United Kingdom based group developing a portfolio of cannabinoid prescription medicines.

Can This Marijuana Stock Add Some Green to Your Portfolio?

Can This Marijuana Stock Add Some Green to Your Portfolio?

Investors in cannabis companies had an eventful 2016 with the approval of recreational marijuana usage in the states of California, Massachusetts, Maine, and Nevada providing a boost to all sorts of marijuana stocks. Of particular note, shares of Corbus Pharmaceuticals (NASDAQ: CRBP) posted a whopping 600% gain in 2016 following positive phase 2 data.

GWPH Phase 3 Results

GW Pharmaceuticals Achieves Positive Results in Phase 2 Proof of Concept Study in Glioma

LONDON, Feb. 7, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive top-line results from an exploratory Phase 2 placebo-controlled clinical study.

Zynerba

Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

DEVON, Pa., Jan. 19, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds to Zynerba of $50.4 million.

GWPH Phase 3 Results

GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome

LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.

Investors Hoping To Ride High On Trailblazing Marijuana Company

Investors Hoping to Ride High on Trailblazing Marijuana Company

With several states passing measures to legalize marijuana in 2016, the cannabis business looks poised to finally to take off. But for investors, there remains a quandary: How do you find a way to get in on the ground floor of this new growth industry?

GWPH Riding High: Stock Rises on Clinical Trial's Positive Results

GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results

On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference

LONDON, Sept. 7, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Third Quarter 2016 Financial Results and Operational Progress

LONDON, Aug. 9, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the third quarter ended 30 June 2016.

GWPH Phase 3 Results

GW Pharmaceuticals plc Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising $289.8 Million on the NASDAQ Global Market and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

LONDON, July 18, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced offering on the NASDAQ Global Market.

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, June 27, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

GWPH Phase 3 Results

GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)

LONDON, June 21, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (“GW” or “the Company”) today announced that the Company has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.

Zynerba

Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences

DEVON, Pa., June 1, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor meetings and conferences.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference and the Jefferies 2016 Healthcare Conference

LONDON, May 31, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Goldman Sachs 37th Annual Global Healthcare Conference.

Insys Therapeutics

Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients

PHOENIX, May 24, 2016 /Weed Wire/ — Insys Therapeutics, Inc. (NASDAQ: INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.

MassRoots Users Funding Round and Crosses Half a Million Users and NASDAQ

Nasdaq Denies Cannabis Technology Company MassRoots; Shuns the Regulated Cannabis Industry

DENVER, May 24, 2016 /Weed Wire/ — MassRoots, Inc. (OTCQB: MSRT), one of the largest and fastest growing technology platforms for the cannabis industry, received notification on Monday, May 23, 2016, that the Nasdaq has denied MassRoots’ application for listing, which was filed in August 2015.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May

LONDON, May 16, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.

Zynerba

Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights

DEVON, Pa., May 12, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the quarter ended March 31, 2016, and provided an overview of recent operational highlights.

GWPH Phase 3 Results

GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress

LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.

GWPH Phase 3 Results

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May

LONDON, May 4, 2016 /Weed Wire/ — GW Pharmaceuticals announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Healthcare Conference on Tuesday, May 10, 2016, at 9:20 a.m. (PDT) at the Encore at the Wynn Las Vegas, Las Vegas, Nev.

Hickenlooper

Hickenlooper at Milken Conference: Colorado Legalization ‘Might Work’

On May 2, 2016, Colorado Gov. John Hickenlooper participated in the Milken Institute Global Conference in Los Angeles, and had the chance to briefly discuss recreational marijuana legalization in Colorado.

GWPH Phase 3 Results

GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex

LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.

Vireo

Vireo Calls on Google to Stop Rejecting Medical Cannabis Ads

NEW YORK, March 18, 2016 /Weed Wire/ — Vireo Health of New York (“Vireo”), one of five companies licensed by the New York State Department of Health to produce and sell medical cannabis, is urging Google (NASDAQ: GOOG) to accept its advertisements using the words ‘medical cannabis’ and ‘medical marijuana.’

GWPH Phase 3 Results

GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)

LONDON, March 14, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome.

Zynerba

Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference

DEVON, Pa., March 7, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will present at the 28th Annual ROTH Conference.

Nemus Bioscience

NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients

COSTA MESA, Calif., and Albany, N.Y., Feb. 8, 2016/ Weed Wire/ —NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced an agreement with Albany Molecular Research Inc. (NASDAQ: AMRI) for the development and manufacture of NEMUS’ proprietary cannabinoid-based active pharmaceutical ingredients.

MassRoots Users Funding Round and Crosses Half a Million Users and NASDAQ

Cannabis Technology Platform MassRoots to Present at CES This Friday, January 8, 2016

DENVER, Jan. 4, 2016 /Weed Wire/ — MassRoots, Inc. (OTCQB:MSRT), one of the largest and fastest growing technology platforms for the cannabis industry, will be presenting on stage at the Consumer Electronics Show (CES) this Friday, January 8, 2016 as part of the semi-finals for the Extreme Tech Challenge.


Page 1 of 212
Top